Every 10-Q that Journey Medical Corporation (DERM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DERM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DERM filings page.
Journey Medical Corporation reported improved operating results for the quarter ended June 30, 2026. Total revenue was $18.5 million, up from $15.0 million a year earlier, driven mainly by Emrosi sales of $8.1 million and new supply and royalty revenue from its Cutia agreement. Net product revenue for the first six months rose to $33.8 million from $28.1 million, while Qbrexza and legacy products declined due to coverage mix and generic competition.
Operating expenses were broadly flat year over year for the quarter, with selling, general and administrative costs declining as Emrosi launch spending eased. The company recorded a small net loss of $0.3 million for the quarter versus a $3.8 million loss in the prior-year quarter, and a $2.5 million loss for the first half versus $7.9 million previously.
Cash and cash equivalents were $25.6 million and working capital was $27.0 million at June 30, 2026. Journey has a $25.0 million term loan outstanding under its SWK Credit Facility and an effective $150.0 million universal shelf registration. Despite better results, the company states that recurring and historical losses raise substantial doubt about its ability to continue as a going concern over the next twelve months.
Journey Medical Corporation reported Q1 2026 revenue of $15.9 million, up 21% from Q1 2025, driven mainly by Emrosi sales of $6.3 million after its recent launch. Qbrexza and Accutane declined modestly, and foam franchise and legacy products fell more sharply due to competition.
The company narrowed its net loss to $2.2 million, or $(0.08) per share, compared with a $4.1 million loss a year earlier, helped by higher sales and stable operating costs. Cash and cash equivalents rose to $27.2 million, aided by positive operating cash flow of $2.9 million in the quarter.
Journey carries a $25.0 million term loan that bears interest at three‑month SOFR plus 7.75%, with principal payments scheduled to begin in February 2027. Despite improved results, management states that recurring and historical losses create substantial doubt about the company’s ability to continue as a going concern over the next twelve months.
Journey Medical reported Q3 2025 results. Total revenue was $17.631 million, up 21% year over year, with product revenue of $17.025 million. Net loss narrowed to $2.315 million (basic and diluted loss per share of $0.09).
Emrosi contributed $4.883 million as its U.S. launch scaled, while Qbrexza delivered $7.361 million. Accutane declined to $2.769 million amid competition. The company also recognized $0.606 million of other revenue from supplying Amzeeq to Cutia.
Cash and cash equivalents were $24.948 million and working capital was $16.7 million as of September 30, 2025. Year-to-date, the company raised $10.939 million via its ATM program (including $6.891 million in Q3). Term loan principal remained $25.0 million; effective interest was 14.47%.
On September 25, 2025, Journey amended its SWK Credit Facility, extending maturity to June 27, 2028 and lowering the revenue threshold for extending the interest-only period to $60.0 million on a trailing twelve-month basis. The company stated that, due to recurring and historical losses, substantial doubt exists about its ability to continue as a going concern.
Journey Medical reported consolidated product revenue of $15.0 million for the quarter ended June 30, 2025, up slightly from $14.9 million a year earlier as the newly launched Emrosi contributed $2.8 million in the quarter while sales of Accutane declined. The company recorded a net loss of $3.8 million for the quarter and $7.9 million for the six months, narrower year-to-date than the prior-year six-month loss of $13.8 million.
At June 30, 2025 the company held $20.3 million in cash, working capital of $10.8 million, total assets of $81.2 million and stockholders' equity of $19.2 million. Debt includes a $25.0 million term loan (net carry amount $25.1 million) with a current portion of $3.75 million and an effective interest rate of about 14.6%. Management discloses substantial doubt about the company’s ability to continue as a going concern due to recurring losses, and gross-to-net reserves increased to $13.9 million, driven by coupon/rebate accruals related to Emrosi.